Associated Papers
Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions.
Rein HL et al.
Nature Communications, 2025
40670332 (PubMed )
Supplement: 41467_2025_61283_MOESM3_ESM.xlsx › Sheet1
Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants.
Prakash R et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.
Möhrmann L et al.
Nature Communications, 2022
35918329 (PubMed )
Supplement: 41467_2022_31866_MOESM7_ESM.xlsx › 4.1_germline_variants
A decade of RAD51C and RAD51D germline variants in cancer.
Boni J et al.
Human Mutation, 2022
Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.
Sullivan MR et al.
Cold Spring Harbor Molecular Case Studies, 2021
Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
Gayarre J et al.
British Journal of Cancer, 2017
Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
Song H et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2015
Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
Cunningham JM et al.
Scientific Reports, 2014
24504028 (PubMed )
Supplement: srep04026-s1.pdf
Select a paper to view details